publications-banner

Information about pipeline products

PublicationView

T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Shitara K, Bang Y-J, Iwasa S, et al.
Nat Med. 2024. doi: 10.1038/s41591-024-02992-x. Epub ahead of print.
Quizartinib
Hematology
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN
Montalban-Bravo G, Jabbour E, Chien K, et al.
Leuk Res. 2024;142:107518.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France
Petit T, Hajjaji N, Antoine E-C, et al.
Cancer Med. 2024;13(9):e7168.
T-DXd
Tumor-agnostic
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): An international, phase 2 study
Li B, Meric-Bernstam F, Bardia A, et al.
Lancet Oncol. 2024;25(6):707-719.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): Patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Fehm T, Cottone F, Dunton K, et al.
Lancet Oncol. 2024;25(5):614-625.
Edoxaban
Cardiovascular - AF
Periprocedural edoxaban management and clinical outcomes in patients undergoing transcatheter cardiovascular procedures in the EMIT-AF/VTE program
Unverdorben M, Colonna P, Jin J, et al.
Clin Appl Thromb Hemost. 2024;30:10760296241260728. doi: 10.1177/10760296241260728.
Dato-DXd
Breast Cancer
TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Bardia A, Pusztai L, Albain K, et al.
Ther Adv Med Oncol. 2024;16:17588359241248336.
Edoxaban
Cardiovascular - AF
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
Kirchhof P, Bakhai A, de Asmundis C, et al.
Int J Cardiol. 2024;408:132118
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
Hurvitz SA, Kim S-B, Chung W-P, et al.
ESMO Open. 2024;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in advanced or metastatic HR+/HER2— and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study
Bardia A, Krop IE, Kogawa T, et al.
J Clin Oncol. 2024 JCO2301909. doi: 10.1200/JCO.23.01909. Epub ahead of print.
Páginas: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer